149 related articles for article (PubMed ID: 30052808)
1. Interleukin 6 trans-signalling and risk of future cardiovascular events.
Ziegler L; Gajulapuri A; Frumento P; Bonomi A; Wallén H; de Faire U; Rose-John S; Gigante B
Cardiovasc Res; 2019 Jan; 115(1):213-221. PubMed ID: 30052808
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 6 trans-signalling and the risk of future cardiovascular events in men and women.
Miri Y; Leander K; Eriksson P; Gigante B; Ziegler L
Open Heart; 2021 Oct; 8(2):. PubMed ID: 34635574
[TBL] [Abstract][Full Text] [Related]
3. The predictive role of interleukin 6 trans-signalling in middle-aged men and women at low-intermediate risk of cardiovascular events.
Ziegler L; Frumento P; Wallén H; de Faire U; Gigante B
Eur J Prev Cardiol; 2020 Jan; 27(2):122-129. PubMed ID: 31438723
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction.
Moreno Velásquez I; Golabkesh Z; Källberg H; Leander K; de Faire U; Gigante B
Atherosclerosis; 2015 Jun; 240(2):477-81. PubMed ID: 25910182
[TBL] [Abstract][Full Text] [Related]
5. Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.
Ziegler L; Lundqvist J; Dreij K; Wallén H; de Faire U; Paulsson-Berne G; Hedin U; Matic L; Gigante B
Vasc Med; 2021 Feb; 26(1):3-10. PubMed ID: 33350884
[TBL] [Abstract][Full Text] [Related]
6. IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation.
Ziegler L; Wallén H; Aspberg S; de Faire U; Gigante B
BMC Neurol; 2021 Aug; 21(1):306. PubMed ID: 34372806
[TBL] [Abstract][Full Text] [Related]
7. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
8. Serum IL8 is not associated with cardiovascular events but with all-cause mortality.
Moreno Velásquez I; Gajulapuri A; Leander K; Berglund A; de Faire U; Gigante B
BMC Cardiovasc Disord; 2019 Feb; 19(1):34. PubMed ID: 30717657
[TBL] [Abstract][Full Text] [Related]
9. Levels of Soluble Interleukin 6 Receptor and Asp358Ala Are Associated With Cognitive Performance and Alzheimer Disease Biomarkers.
Quillen D; Hughes TM; Craft S; Howard T; Register T; Suerken C; Hawkins GA; Milligan C
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 36810164
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels.
Wonnerth A; Katsaros KM; Krychtiuk KA; Speidl WS; Kaun C; Thaler K; Huber K; Wojta J; Maurer G; Seljeflot I; Arnesen H; Weiss TW
Metabolism; 2014 May; 63(5):647-53. PubMed ID: 24629561
[TBL] [Abstract][Full Text] [Related]
11. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.
Widjaja AA; Cook SA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338642
[TBL] [Abstract][Full Text] [Related]
12. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease.
Lemmers A; Gustot T; Durnez A; Evrard S; Moreno C; Quertinmont E; Vercruysse V; Demetter P; Franchimont D; Le Moine O; Geerts A; Devière J
Clin Exp Immunol; 2009 Jun; 156(3):518-27. PubMed ID: 19438606
[TBL] [Abstract][Full Text] [Related]
13. Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness.
Weiss TW; Arnesen H; Seljeflot I
Metabolism; 2013 Jul; 62(7):1008-13. PubMed ID: 23428306
[TBL] [Abstract][Full Text] [Related]
14. Contemplating IL-6, a double-edged sword cytokine: Which side to use for stroke pathology?
Monsour M; Croci DM; Agazzi S; Borlongan CV
CNS Neurosci Ther; 2023 Feb; 29(2):493-497. PubMed ID: 36478506
[TBL] [Abstract][Full Text] [Related]
15. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of sgp130 and sex hormones in male patients with coronary atherosclerotic disease.
Cui Y; Dai W; Li Y
Atherosclerosis; 2017 Nov; 266():151-157. PubMed ID: 29028483
[TBL] [Abstract][Full Text] [Related]
17. IL-6 Transsignaling in Patients with Chronic Spontaneous Urticaria.
Kasperska-Zajac A; Grzanka A; Damasiewicz-Bodzek A
PLoS One; 2015; 10(12):e0145751. PubMed ID: 26699882
[TBL] [Abstract][Full Text] [Related]
18. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis.
Korotaeva AA; Samoilova EV; Chepurnova DA; Zhitareva IV; Shuvalova YA; Prokazova NV
Biomarkers; 2018 Sep; 23(6):527-532. PubMed ID: 29580104
[TBL] [Abstract][Full Text] [Related]
19. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
20. Effects of diet and/or n-3 fatty acid supplementation on components of the interleukin-6 trans-signalling system in elderly men.
Andric T; Weiss TW; Huber K; Arnesen H; Seljeflot I
Scand J Clin Lab Invest; 2015; 75(8):646-51. PubMed ID: 26179891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
